204 related articles for article (PubMed ID: 33781961)
1. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
[TBL] [Abstract][Full Text] [Related]
3. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Zeng Y; Li C; Guan M; Zheng Z; Li J; Xu W; Wang L; He F; Xue Y
Cardiovasc Diabetol; 2014 Feb; 13():32. PubMed ID: 24490809
[TBL] [Abstract][Full Text] [Related]
4. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Ervinna N; Mita T; Yasunari E; Azuma K; Tanaka R; Fujimura S; Sukmawati D; Nomiyama T; Kanazawa A; Kawamori R; Fujitani Y; Watada H
Endocrinology; 2013 Mar; 154(3):1260-70. PubMed ID: 23337530
[TBL] [Abstract][Full Text] [Related]
5. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Vittone F; Liberman A; Vasic D; Ostertag R; Esser M; Walcher D; Ludwig A; Marx N; Burgmaier M
Diabetologia; 2012 Aug; 55(8):2267-75. PubMed ID: 22648661
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
9. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Ta NN; Schuyler CA; Li Y; Lopes-Virella MF; Huang Y
J Cardiovasc Pharmacol; 2011 Aug; 58(2):157-66. PubMed ID: 21558879
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2.
Ning MM; Yang WJ; Guan WB; Gu YP; Feng Y; Leng Y
Acta Pharmacol Sin; 2020 Nov; 41(11):1446-1456. PubMed ID: 32398684
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice.
Lin CP; Huang PH; Chen CY; Wu MY; Chen JS; Chen JW; Lin SJ
Sci Rep; 2021 Sep; 11(1):17851. PubMed ID: 34497344
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.
Brenner C; Franz WM; Kühlenthal S; Kuschnerus K; Remm F; Gross L; Theiss HD; Landmesser U; Kränkel N
Int J Cardiol; 2015 Nov; 199():163-9. PubMed ID: 26197403
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.
Shirakawa J; Amo K; Ohminami H; Orime K; Togashi Y; Ito Y; Tajima K; Koganei M; Sasaki H; Takeda E; Terauchi Y
J Biol Chem; 2011 Jul; 286(29):25467-76. PubMed ID: 21613229
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
[TBL] [Abstract][Full Text] [Related]
19. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
